(:VRAY)

Jul 21, 2023 04:01 pm ET
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets
DENVER, July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (Nasdaq: VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock M
Jul 17, 2023 07:00 am ET
ViewRay® Files Voluntary Chapter 11 Petitions
Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process
Jun 13, 2023 06:00 am ET
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System
First cancer center in Oklahoma and fourth VA medical center to offer advanced MRI-guided radiation therapy to treat cancer.
May 12, 2023 06:30 am ET
ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting
50 clinical presentations and posters highlight benefits of MRI-guided radiation adaptive therapy
May 10, 2023 04:01 pm ET
ViewRay Announces First Quarter 2023 Results
DENVER, May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023.
May 09, 2023 04:10 pm ET
ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023
DENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of first quarter 2023 financial results.
Apr 13, 2023 06:00 am ET
ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value
DENVER, April 13, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today provided a business update and announced preliminary financial results for the quarter ended March 31, 2023. The preliminary results have not been audited and are subject to change.
Apr 12, 2023 05:25 pm ET
ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023
DENVER, April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786. The confirmation number is 56031524. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars.
Feb 27, 2023 03:05 pm ET
ViewRay Announces Fourth Quarter and Full Year 2022 Results
DENVER, Feb. 27, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022.
Jan 31, 2023 05:30 am ET
ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023
DENVER, Jan. 31, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of fourth quarter 2022 financial results.
Jan 20, 2023 04:05 pm ET
ViewRay Enters into Cooperation Agreement with Hudson Executive Capital
CLEVELAND, Jan. 20, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the ViewRay Board of Directors (the "Board"), effective as of January 20, 2023.
Jan 12, 2023 10:53 am ET
Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
MIRAGE phase III randomized controlled trial shows a significant reduction in GU and GI toxicities with MRIdian® MRI-guided versus CT-guided SBRT
Jan 09, 2023 05:00 am ET
ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer
DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change.
Jan 05, 2023 08:41 am ET
Chindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer Treatment
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Jan 05, 2023 05:00 am ET
University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems
Immediate order of one system with ability to purchase an additional three systems
Nov 14, 2022 04:15 pm ET
ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility
Facility includes senior secured term loan of up to $100 million and a revolving line of credit of up to $25 million
Nov 14, 2022 05:30 am ET
ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference
DENVER, Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the 34th Annual Piper Sandler Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 9:30 a.m. Eastern Time on Wednesday, November 30, 2022.
Nov 10, 2022 05:30 am ET
ViewRay® to Present at the Stifel 2022 Healthcare Conference
DENVER, Nov. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Stifel 2022 Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 2:25 p.m. Eastern Time on Tuesday, November 15, 2022.
Nov 01, 2022 05:18 pm ET
ViewRay Announces Third Quarter 2022 Results
DENVER, Nov. 1, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022.
Oct 27, 2022 06:30 am ET
MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Final outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- vs. CT-guided prostate SBRT presented at ASTRO 2022
Oct 24, 2022 06:30 am ET
ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients
Study's primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART
Oct 19, 2022 06:30 am ET
MRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022
Clinical outcome oral presentations on SMART Pancreas and MIRAGE prostate studies
Oct 18, 2022 06:30 am ET
ViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy
Prospective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherapy alone
Oct 14, 2022 06:30 am ET
ViewRay Announces Conference Call for Third Quarter 2022 Financial Results to be Held After Market on November 1, 2022
DENVER, Oct. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of third quarter 2022 financial results.
Oct 06, 2022 06:30 am ET
SUNY Upstate Cancer Center Chooses ViewRay's MRI-Guided Radiation Therapy System to Treat Cancer Patients
Becomes First Cancer Center in Upstate New York to offer the Advanced Precision of MRIdian® MRI-Guided Radiation Therapy
Oct 04, 2022 06:30 am ET
San Pietro Fatebenefratelli Hospital Treats its 1,000th Patient with MRIdian® MRI-Guided Radiation Therapy
Italian hospital reaches patient milestone in less than three years using MRIdian's real-time, on-table adaptive capabilities
Oct 03, 2022 06:30 am ET
ViewRay to host Investor Day
DENVER, Oct. 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today plans to host an Investor Day on Thursday, November 17, 2022, at 8:00 a.m. Eastern Time in New York City, NY.
Sep 20, 2022 06:30 am ET
MD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy Program
First MRIdian system to be installed at MD Anderson main campus at the Texas Medical Center in Houston
Sep 09, 2022 06:30 am ET
ViewRay® to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
DENVER, Sept. 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 8:00 a.m. Eastern Time on Tuesday, September 13, 2022.
Sep 08, 2022 06:30 am ET
Sep 07, 2022 06:30 am ET
ViewRay Announces China NMPA Approval of its MRIdian® MRI-Guided Radiation Therapy for Cancer Patients
This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option—MRIdian SMART
Aug 23, 2022 06:30 am ET
VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
This is the First Hospital in Texas and the Third VA Hospital to Offer MRIdian® MRI-guided Radiation Therapy Cancer Treatment.
Aug 11, 2022 06:30 am ET
National Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patients
Largest Cancer Center in Japan Enhances its Real-Time Soft-Tissue Tracking and On-Table Adaptive Delivery with MRIdian System
Aug 08, 2022 06:00 am ET
ViewRay Selects Denver for Headquarters
Innovative cancer therapy company to leverage Colorado bioscience talent resources
Aug 02, 2022 04:01 pm ET
ViewRay and Katie Couric Media Partner to Raise Awareness about MRIdian® MRI-Guided Radiation Therapy
Multiyear campaign will highlight clinical evidence and patient impact of MRIdian for cancer treatment
Aug 02, 2022 04:01 pm ET
ViewRay Announces Second Quarter 2022 Results
CLEVELAND, Aug. 2, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2022.
Jul 29, 2022 09:48 am ET
Centre Oscar Lambret Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System
Represents the first in Lille, France to Bring the Benefits of Precision Radiation Therapy to the Hauts de France Region
Jul 19, 2022 07:00 am ET
Saitama Medical University International Medical Center Selects MRIdian® MRI-Guided Radiation Therapy System
CLEVELAND, July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Saitama Medical University International Medical Center has purchased a MRIdian MRI-Guided Radiation Therapy System to complete its newly built comprehensive cancer center in Yamane, Hidaka-City. The MRIdian system will enable Saitama Medical University to offer advanced MRI-guided radiation therapy technology to cancer patients who are seeking personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.
Jul 19, 2022 06:30 am ET
ViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022
CLEVELAND, July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results.
Jun 09, 2022 06:30 am ET
VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
Represents Second VA Hospital to Offer MRIdian MRI-guided Radiation Therapy Cancer Treatment Directly to Veterans
Jun 07, 2022 06:30 am ET
Shin-Matsudo Central General Hospital Select's ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Expand Access to Precision Radiation Therapy
CLEVELAND, June 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy (SMART) Center in Japan. This is the third MRIdian system in Japan intended to help address an unmet need with a growing population and an increasing rate of cancer patients in Toukatsu. The center expects to begin patient treatments in the early Fall of 2023.
Jun 02, 2022 06:30 am ET
Henry Ford Health Becomes the First Center to Treat Patients with ViewRay's MRIdian A3i System
New MRIdian A3i features will enable the Henry Ford team to streamline on-table workflow, reduce treatment times, and expand clinical utility to brain treatments
May 10, 2022 06:30 am ET
Clinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presented at ESTRO 2022
Retrospective analysis shows MRIdian's small treatment margins enabled by adaptation and real-time tracking and automated beam control may allow for ablative radiation with minimal toxicity in hard to treat lung lesions
May 06, 2022 12:01 am ET
MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology Meeting
ViewRay celebrates 10-years as the first and only company to offer real-time tissue tracking with automatic beam gating and will host a lunch symposium highlighting new MRIdian A3i features  
May 05, 2022 04:01 pm ET
ViewRay Announces First Quarter 2022 Results
CLEVELAND, May 5, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2022.
May 03, 2022 06:30 am ET
UCI Health Adopts ViewRay® MRIdian® MRI-Guided Radiation Therapy System
MRIdian will be the First MRI-Guided Radiation Therapy System at the UCI Chao Family Comprehensive Cancer Center facility opening in late 2023
Apr 21, 2022 08:30 am ET
ViewRay Announces Conference Call for First Quarter 2022 Financial Results to be Held After Market on May 5, 2022
CLEVELAND, April 21, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results.
Mar 15, 2022 06:30 am ET
University Hospital Agostino Gemelli Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy
Center Becomes First MRIdian Program in Southern Europe to Reach this Treatment Milestone
Mar 10, 2022 11:00 am ET
ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022
CLEVELAND, March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Wednesday, March 16, 2022. The event will begin at 4:00 pm ET.
Mar 10, 2022 05:30 am ET
First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer
CLEVELAND, March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the first toxicity results from the prospective single-arm Phase II SCIMITAR trial. A secondary analysis compared the findings of treatment under CT-guidance to MRI-guidance and found that patients treated with MRI-guidance had a 30.5 percent reduction in any grade acute GI toxicity and a 32 percent reduction in any grade cumulative GI toxicity up to 6 months. No patient treated with MRI-guided radiation therapy experienced any grade 3 GU or GI toxicity. Initial toxicity results are being presented by UCLA
Mar 09, 2022 03:01 pm ET
ViewRay Enters into Cooperation Agreement with Hudson Executive Capital
CLEVELAND, March 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Susan Schnabel to the ViewRay Board of Directors (the "Board") as an independent director, effective as of March 8, 2022.
Mar 03, 2022 05:30 am ET
Acibadem Group Purchases Second MRIdian® System for Acibadem Altunizade Hospital in Istanbul
CLEVELAND, March 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Acibadem Group, one of the leading private healthcare service institutions in Turkey, has purchased a second MRIdian MRI-guided radiation therapy system for installation at the Acibadem Altunizade Hospital in Istanbul, Turkey.
Feb 24, 2022 03:01 pm ET
ViewRay Announces Fourth Quarter and Full Year 2021 Results
CLEVELAND, Feb. 24, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2021.
Feb 15, 2022 05:30 am ET
Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
CLEVELAND, Feb. 15, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that interim data from the single center Phase III randomized MIRAGE trial, led by UCLA, comparing MRIdian MRI-guided vs. CT-guided SBRT for localized prostate cancer, will be featured at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, held February 17-19 in San Francisco. Interim analysis of the primary endpoint signaled superiority of MRIdian MRI-guided SBRT with a significant reduction in acute grade ≥2 GU toxicity in men receiving MRI-guided SBRT over those re
Feb 10, 2022 07:00 am ET
ViewRay Announces Conference Call for Fourth Quarter and Full Year 2021 Financial Results to be Held After Market on February 24, 2022
CLEVELAND, Feb. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2021 financial results.
Feb 10, 2022 07:00 am ET
ViewRay® to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
CLEVELAND, Feb. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Zach Stassen, Chief Financial Officer, and Paul Strong VP, Clinical Affairs, will participate in a virtual fireside chat at 3:00 p.m. Eastern Time on Thursday, February 17, 2022. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
Feb 09, 2022 05:30 am ET
University Hospital Halle (Saale) Selects ViewRay's MRIdian® System to Broaden Advanced Radiation Therapy Treatment Services
CLEVELAND, Feb. 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospital Halle (Saale) in Germany has purchased a MRIdian MRI-guided radiation therapy system for installation at the University Hospital´s Krukenberg Cancer Center, the academic provider of cancer services in Southern Saxony-Anhalt with specialized treatment drawing patients from adjacent states and nationally.
Jan 10, 2022 07:49 am ET
ViewRay Announces Preliminary Fourth Quarter and Full Year 2021 Results
CLEVELAND, Jan. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2021. The preliminary results have not been audited and are subject to change.
Dec 23, 2021 03:15 pm ET
ViewRay to Participate in the 40th Annual J.P. Morgan Healthcare Conference
CLEVELAND, Dec. 23, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference.
Dec 15, 2021 05:30 am ET
ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features
CLEVELAND, Dec. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company received FDA 510(k) clearance for its next generation of MRI-guided radiation therapy features, focused on enhancing on-table adaptive workflow and expanding clinical utility. MRIdian A3i includes a suite of new features to streamline on-table adaptive workflow and provide the potential to reduce treatment times, along with a new brain treatment package expanding clinical utility into cranial stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT).
Dec 07, 2021 05:30 am ET
Northside Hospital Chooses MRIdian System to Expand Advanced Radiation Therapy Treatment Services
CLEVELAND, Dec. 7, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Northside Hospital in Georgia has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy treatment services at its Northside Hospital Cancer Institute in Atlanta.
Nov 24, 2021 05:30 am ET
ViewRay Announces MRIdian MR-Guided Radiation Therapy Surpasses 2,300 Pancreatic Cancer Patients Treated Worldwide
CLEVELAND, Nov. 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced, in recognition of Pancreatic Cancer Awareness Month, more than 2,300 pancreatic cancer patients have been treated with MRIdian at 46 centers around the world. ViewRay would like to recognize the global clinical teams providing options for patients who otherwise may not have been offered treatment. This enables more personalized treatment and helps further improve the precision of treatment. To date, 90 percent of MRIdian centers are treating pancreatic cancer in 5 sessions with an ablative treatment dose t
Nov 23, 2021 10:30 am ET
ViewRay Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in connection with Public Offering of Common Stock
CLEVELAND, Nov. 23, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the closing of an additional 1,875,000 shares of common stock following the exercise in full of the underwriters' option to purchase additional shares in connection with its recently completed public offering of 12,500,000 shares of common stock, for additional gross proceeds of $10.5 million for total gross proceeds of $80.5 million, before deducting underwriting discounts and co
Nov 19, 2021 10:53 am ET
ViewRay Announces Closing of Public Offering of Common Stock
CLEVELAND, Nov. 19, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 12,500,000 shares of common stock at a price to the public of $5.60 per share, for gross proceeds of approximately $70.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.  All of the shares sold in the offering were sold by ViewRay.  In addi
Nov 16, 2021 09:16 pm ET
ViewRay Announces Pricing of Public Offering of Common Stock
CLEVELAND, Nov. 16, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 12,500,000 shares of common stock at a price to the public of $5.60 per share, for gross proceeds of $70 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.  All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the
Nov 16, 2021 03:05 pm ET
ViewRay Announces Proposed Public Offering of Common Stock
CLEVELAND, Nov. 16, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of shares of its common stock.  In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commissions.  All of the shares of common stock to be sold in the offering will be o
Nov 04, 2021 04:01 pm ET
ViewRay Reports Third Quarter 2021 Results
CLEVELAND, Nov. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2021.
Oct 28, 2021 06:30 am ET
New Outcomes Data Demonstrating Prolonged Survival for Inoperable Pancreatic Cancer Patients Presented at Leading Radiation Oncology Meeting
CHICAGO, Oct. 28, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the results of a multi-center study of 148 inoperable pancreatic cancer patients treated with MRIdian SMART (MR-guided stereotactic adaptive radiation therapy) were presented as part of the Annual Meeting of the American Society for Radiation Oncology (ASTRO), the world's largest radiation oncology society, held October 24-27, 2021 in Chicago. The results, presented on October 27 by Michael Chuong, M.D., medical director of radiation oncology at the Miami Cancer Institute, part of Baptist Health South Fl
Oct 25, 2021 06:30 am ET
Helsinki University Hospital Selects MRIdian® System for Installation at Comprehensive Cancer Center
CLEVELAND, Oct. 25, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Helsinki University Hospital has purchased a MRIdian® System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital.
Oct 22, 2021 06:30 am ET
Baptist Health South Florida to Acquire a Second ViewRay MRIdian® MR-Guided Radiation Therapy System
CLEVELAND, Oct. 22, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Baptist Health South Florida will acquire  a second MRIdian MR-guided radiation therapy system, joining other leading institutions from around the globe investing in multiple MRIdian systems. Baptist Health is expanding its MRIdian MR-guided radiation therapy services at Lynn Cancer Institute, part of Baptist Health South Florida. This purchase complements Baptist Health's current MRIdian program at Miami Cancer Institute which has been using the MR-Linac to treat patients since 2018, and makes Lynn Ca
Oct 18, 2021 05:54 pm ET
ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on October 28, 2021
CLEVELAND, Oct. 18, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Thursday, October 28, 2021. The event will begin at 8:30 am ET / 5:30 am PT.
Oct 14, 2021 08:30 am ET
ViewRay Announces Conference Call for Third Quarter 2021 Financial Results to be Held After Market on November 4, 2021
CLEVELAND, Oct. 14, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2021 financial results.
Sep 29, 2021 01:44 pm ET
ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations
CLEVELAND, Sept. 29, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company has received acceptance from the FDA on their recent submission for new MRIdian features focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility. ViewRay will be exhibiting at the annual ASTRO 2021 conference in Chicago, IL from October 24― October 26 and will be highlighting the new technological advancements during the conference.
Sep 16, 2021 04:01 pm ET
ViewRay® to Partcipate in the Cantor Global Healthcare Conference
CLEVELAND, Sept. 16, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the Cantor Global Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 10:00 a.m. Eastern Time on Tuesday, September 28, 2021.
Aug 27, 2021 04:01 pm ET
ViewRay® to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CLEVELAND, Aug. 27, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Morgan Stanley 19th Annual Global Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 10:15 a.m. Eastern Time on Friday, September 10, 2021.
Aug 24, 2021 06:30 am ET
Amsterdam University Medical Centers establishes same-day ablative treatment service using MRIdian® to Streamline the Patient Experience.
CLEVELAND, Aug. 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has started offering "same-day ablative treatment" using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy) for patients who are eligible for single fraction MRI-guided radiation therapy. Three patients under treatment for lung tumors were the first to benefit from this program. Typically, patients undergoing radiation therapy are required to make several visits to the hospital from consultation, through planning scan t
Aug 17, 2021 06:30 am ET
UCLA Health Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy
CLEVELAND, Aug. 17, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that UCLA Health joins the Siteman Cancer Center at Washington University, Seoul National University Hospital and Amsterdam UMC in surpassing the treatment of 1,000 patients using the MRIdian® MRI-guided radiation therapy system. UCLA Health is the fourth MRIdian center to reach this treatment milestone in bringing the benefits of MRI-guided radiation therapy to cancer patients.
Aug 05, 2021 04:01 pm ET
ViewRay Reports Second Quarter 2021 Results
CLEVELAND, Aug. 5, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2021.
Jul 15, 2021 08:30 am ET
ViewRay Announces Conference Call for Second Quarter 2021 Financial Results to be Held After Market on August 5, 2021
CLEVELAND, July 15, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2021 financial results.
Jul 07, 2021 09:31 am ET
Thinking about buying stock in Opiant Pharmaceuticals, RealNetworks, Vaxart, Clover Health, or Viewray?
NEW YORK, July 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPNT, RNWK, VXRT, CLOV, and VRAY.
Jul 07, 2021 06:30 am ET
Miami Cancer Institute Enrolls First Patients in Single-Fraction Stereotactic MRI-Guided Adaptive Radiation Therapy for Inoperable Primary or Metastatic Cancer Trial
CLEVELAND, July 7, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Miami Cancer Institute, part of Baptist Health South Florida, has enrolled the first patients in its "Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction for Inoperable Primary or Metastatic Carcinoma" clinical study – referred to as the SMART ONE trial (NCT#04939246). This single-arm prospective study that was developed and led by Dr. Michael Chuong, MD, FACRO, radiation oncologist and Medical Director of Proton Therapy and MR-guided Therapy at Miami Cancer Institute, is expl
Jun 24, 2021 08:30 am ET
GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian® Systems
Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets
Jun 24, 2021 08:30 am ET
GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian® Systems
Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets
Jun 24, 2021 06:00 am ET
Cancer Patients Across the U.S. to Benefit from GenesisCare's Partnership with ViewRay, Inc.
FORT MYERS, Fla., June 24, 2021 /PRNewswire/ -- GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—today announced it expanded its partnership with ViewRay, Inc. (NASDAQ: VRAY) by purchasing new MRIdian® MR-Guided Therapy Systems to offer personalized and precise radiation therapy. The MRIdian system provides oncologists unprecedented acute visualization through diagnostic-quality MR images and the ability to adapt to target cancer in real-time, aligning with GenesisCare's mission to provide the most advanced treatments to its pat
Jun 11, 2021 04:01 pm ET
ViewRay Announces Election of Karen N. Prange to its Board of Directors
CLEVELAND, June 11, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced the election of Karen N. Prange to its Board of Directors by ViewRay's stockholders at its 2021 Annual Meeting, effective today.
Feb 19, 2021 03:01 pm ET
ViewRay Announces Conference Call for Fourth Quarter and Full Year 2020 Financial Results to be Held After Market on March 4, 2021
CLEVELAND, Feb. 19, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2020 financial results.
Feb 11, 2021 03:01 pm ET
ViewRay Announces Appointment of Phil Spencer to its Board of Directors
CLEVELAND, Feb. 11, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Phil Spencer to its Board of Directors, effective February 9, 2021.
Feb 11, 2021 05:30 am ET
Penn State Health Purchases Second ViewRay MRIdian® Linac
CLEVELAND, Feb. 11, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Penn State Health has purchased a second MRIdian Linac joining other pioneering institutions from around the globe investing in multiple MRIdian systems. Penn State Health's first MRIdian Linac will be installed at the Penn State Health Milton S. Hershey Medical Center.
Jan 26, 2021 05:30 am ET
The Henry Ford Cancer Institute Installs its Second ViewRay MRIdian® Linac
CLEVELAND, Jan. 26, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Henry Ford Cancer Institute has installed its second MRIdian Linac at its new cancer pavilion, Henry Ford Cancer Institute – Detroit, which began offering patient care on January 20, 2021.
Jan 15, 2021 07:30 am ET
ViewRay Announces Participation in the B. Riley Oncology Investor Conference
CLEVELAND, Jan. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in a fireside chat at the B. Riley Oncology Investor Conference on Wednesday, January 20, 2021. ViewRay will also be hosting 1x1 meetings with investors.
Jan 07, 2021 03:01 pm ET
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
CLEVELAND, Jan. 7, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 11,856,500 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $57.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares sold in the offering were sold by ViewRay. The shares
Jan 04, 2021 09:53 pm ET
ViewRay Announces Pricing of Public Offering of Common Stock
CLEVELAND, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 10,310,000 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay ha
Jan 04, 2021 04:06 pm ET
ViewRay Announces Proposed Public Offering of Common Stock
CLEVELAND, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold in the offering will be offe
Jan 04, 2021 07:30 am ET
Thinking about buying stock in Ocugen, BioNano Genomics, FLIR Systems, Clearside Biomedical, or Viewray?
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, BNGO, FLIR, CLSD, and VRAY.
Jan 04, 2021 06:30 am ET
ViewRay Announces Preliminary Fourth Quarter and Full Year 2020 Results
CLEVELAND, Ohio, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2020. The preliminary results have not been audited and are subject to change.
Dec 23, 2020 07:30 am ET
ViewRay to Present at the 39th Annual J.P. Morgan Healthcare Conference
CLEVELAND, Dec. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. Scott Drake, President and CEO, is scheduled to present at 10:50 a.m. Eastern Time on Thursday, January 14, 2021.
Dec 22, 2020 05:30 am ET
Seoul National University Hospital Treats 1,000th Patient with MRIdian MRI-Guided Radiation Therapy
CLEVELAND, Dec. 22, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Seoul National University Hospital (SNUH), a leading healthcare facility in South Korea, has treated one thousand patients using the MRIdian System.
Dec 21, 2020 05:30 am ET
Eindhoven's Catharina Hospital Purchases ViewRay's MRIdian Linac
CLEVELAND, Dec. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Catharina Hospital in Eindhoven, Netherlands, also known as Catharina Ziekenhuis, has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.
Nov 23, 2020 07:00 am ET
ViewRay to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
CLEVELAND, Nov. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.
Nov 12, 2020 05:30 am ET
Amsterdam University Medical Centers Treats 1,000th Patient with MRIdian SMART MRI-Guided Radiation Therapy
CLEVELAND, Nov. 12, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has treated one thousand patients using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy). Amsterdam UMC continues to advance the practice of high-dose ablative radiation therapy with MRIdian through research and publication of the center's findings.
Nov 10, 2020 05:30 am ET
Leading Academic Clinical Training Hospital, Universitair Ziekenhuis Brussels, Purchases ViewRay's MRIdian Linac
CLEVELAND, Nov. 10, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Universitair Ziekenhuis Brussels has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.
Nov 05, 2020 03:05 pm ET
ViewRay Reports Third Quarter 2020 Results
CLEVELAND, Nov. 5, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2020.
Oct 21, 2020 06:30 am ET
ASTRO 2020 to Feature Latest MRIdian Clinical Experience Highlighting Outcomes in Tough to Treat Cancer
CLEVELAND, Oct. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® Linac MRI-guided radiation therapy system will be featured at the 2020 Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held virtually October 24 to 28, 2020. The meeting will feature presentations that showcase the MRIdian system, including how clinicians use this cutting-edge Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) technology to tackle both tough-to-treat and ubiquitous cancer, expand clinical experience with the device, and impact
Oct 15, 2020 08:00 am ET
ViewRay Announces Conference Call for Third Quarter 2020 Financial Results to be Held After Market on November 5, 2020
CLEVELAND, Oct. 15, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2020 financial results.
Oct 14, 2020 06:30 am ET
Louis Stokes Cleveland VA Medical Center Purchases ViewRay's MRIdian Linac for MRI-Guided Radiation Therapy
CLEVELAND, Oct. 14, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the Louis Stokes Cleveland VA Medical Center in Cleveland, Ohio has purchased the MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.
Oct 06, 2020 08:00 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Pilgrim’s Pride Corporation, Resideo Technologies, Spirit Aerosystems, and ViewRay and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Pilgrim’s Pride Corporation (NASDAQ: PPC), Resideo Technologies, Inc. (NYSE: REZI), Spirit AeroSystems Holdings,...
Aug 05, 2020 06:30 am ET
Kaohsiung Medical University Chung-Ho Memorial Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
CLEVELAND, Aug. 5, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) in Kaohsiung City, Taiwan has begun patient treatments with the MRIdian® MR-Guided Radiation Therapy System, a cutting-edge device that delivers personalized cancer care by combining the latest innovations in precision radiation delivery with ground-breaking MR-guidance. The first two patients treated at KMUH on MRIdian were provided care for prostate cancer and tumor lesions in the left lung. Both treatments took advantage of MRIdian's auto
Jul 30, 2020 04:01 pm ET
ViewRay Reports Second Quarter 2020 Results
CLEVELAND, July 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020.
Jul 13, 2020 08:00 am ET
ViewRay Announces Conference Call for Second Quarter 2020 Financial Results to be Held After Market on July 30, 2020
CLEVELAND, July 13, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2020 financial results.
Jul 02, 2020 08:48 pm ET
Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?
SAN DIEGO, July 2, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of the companies listed below.
Jun 23, 2020 08:00 am ET
ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers
CLEVELAND, June 23, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the publication by the European Urology Oncology Journal of a prospective phase II study of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. The publication is a follow-up to early outcomes published in 2019 which reported low incidence of acute toxicity in both clinician- and patient-reported outcomes. The one-year data reported continued absence of grade 3 or higher toxicities and reductions in long-term patient-reported outcome measures after MRIdian treatment. Researchers
Jun 03, 2020 07:30 pm ET
ViewRay Announces Equity Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 3, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today grants of stock options and restricted stock units to Zach Stassen, Chief Financial Officer for the company.  These awards were granted as an inducement material to entering into employment with ViewRay, in accordance with Nasdaq Listing Rule 5635(c)(4) and as approved by the Compensation Committee of ViewRay's Board of Directors.
Jun 03, 2020 07:32 am ET
Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?
SAN DIEGO, June 3, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of the companies listed below.
May 28, 2020 08:00 am ET
ViewRay® to Present at the Jefferies 2020 Virtual Healthcare Conference
CLEVELAND, May 28, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Jefferies 2020 Virtual Healthcare Conference. Scott Drake, President and CEO, will participate in a fireside chat at 2:30 p.m. Eastern Time on Tuesday, June 2, 2020.
May 27, 2020 06:30 am ET
Providence Portland Medical Center Begins Patient Treatments with ViewRay's MRIdian Linac
CLEVELAND, May 27, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Providence Portland Medical Center in Portland, Oregon has begun patient treatments with the MRIdian® MR-Guided Therapy System, a cutting-edge radiation therapy system that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.
Apr 30, 2020 04:01 pm ET
ViewRay Names Zach Stassen as Chief Financial Officer
CLEVELAND, April 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Zach Stassen has been named Chief Financial Officer, effective May 18, 2020. Mr. Stassen will report directly to Scott Drake, President and Chief Executive Officer.
Apr 30, 2020 04:01 pm ET
ViewRay Reports First Quarter 2020 Results
CLEVELAND, April 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the first quarter ended March 31, 2020.
Apr 16, 2020 04:01 pm ET
ViewRay Announces Appointment of B. Kristine Johnson to its Board of Directors
CLEVELAND, April 16, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of B. Kristine Johnson to its Board of Directors effective April 14, 2020.
Apr 09, 2020 06:30 am ET
ViewRay Announces Conference Call for First Quarter 2020 Financial Results to be Held After Market on April 30, 2020
CLEVELAND, April 9, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2020 financial results.
Apr 01, 2020 06:30 am ET
ViewRay and VieCure Announce Strategic Collaboration to Accelerate Adoption of Personalized Cancer Care
CLEVELAND, April 1, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today a strategic collaboration with VieCure, an artificial intelligence (AI) informatics company with a leading point-of-care clinical decision support platform and a comprehensive electronic medical record (EMR) in oncology. The collaboration is designed to drive personalized care and treatment to patients by educating oncology practices on both companies' precision oncology solutions.
Mar 19, 2020 06:30 am ET
Enloe Medical Center Becomes First Community Hospital in Northern California to Purchase a MRIdian MRI-Guided Radiation Therapy System
CLEVELAND, March 19, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Enloe Medical Center – an independent, nonprofit hospital in Chico, California– has entered into a master agreement for the purchase of a MRIdian MRI-guided radiation therapy system. Upon installation, Enloe Medical Center will become the first community hospital in Northern California to offer MRIdian treatments.
Mar 18, 2020 06:30 am ET
Ludwig-Maximilians-University Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
CLEVELAND, March 18, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Ludwig-Maximilians-University Hospital in Munich has begun patient treatments with MRIdian® Linac, a cutting-edge radiation therapy system that combines the latest innovations in precision radiation delivery and ground-breaking MRI-guidance.
Nov 14, 2019 08:33 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Meredith Corporation, McKesson Corporation, Maxar Technologies, and ViewRay and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of Meredith Corporation (NYSE: MDP), McKesson Corporation (NYSE: MCK), Maxar Technologies, Inc. (NYSE: MAXR), and ViewRay,...
Nov 12, 2019 03:01 pm ET
ViewRay Reports Third Quarter 2019 Results
CLEVELAND, Nov. 12, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter ended September 30, 2019.
Nov 12, 2019 10:30 am ET
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against ViewRay, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ViewRay, Inc. (“ViewRay” or “the Company”) (NASDAQ:
Nov 12, 2019 10:13 am ET
CLASS ACTION UPDATE for VRAY, SDC, TEUM and QUAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 12, 2019 09:00 am ET
INVESTOR ALERT - ViewRay, Inc. (VRAY) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: November 12, 2019
NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ViewRay, Inc.  ("ViewRay"  or "the Company") (NASDAQ: VRAY) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ViewRay securities between March 15, 2019 and August 8, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/vray.    
Nov 11, 2019 11:00 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of VRAY and OLLI of Upcoming Deadlines
Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies: ViewRay, Inc. (NASDAQ GS: VRAY) Class Period: March 15, 2019 – August 8, 2019Lead...
Nov 11, 2019 10:50 pm ET
VIEWRAY 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against ViewRay, Inc
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 12, 2019 to file lead plaintiff applications in a securities class action lawsuit...
Nov 11, 2019 09:41 am ET
SHAREHOLDER ALERT: PUMP MGNX VRAY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 09, 2019 07:13 pm ET
3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds ViewRay (VRAY) Investors of November 12th Lead Plaintiff Deadline, Encourages Investors with Significant Losses to Contact the Fi
Hagens Berman urges ViewRay, Inc. (NASDAQ: VRAY) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify to recover their investment losses. The November 12, 2019 lead plaintiff deadline in a...
Nov 09, 2019 12:45 pm ET
ROSEN, A LEADING GLOBAL LAW FIRM, Reminds ViewRay, Inc. Investors of Important November 12th Deadline in Securities Class Action – VRAY
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ViewRay, Inc. (NASDAQ: VRAY) from March 15, 2019 through August 8, 2019, inclusive (the “Class Period”) of the important November 12, 2019 lead plaintiff...
Nov 08, 2019 10:50 pm ET
VIEWRAY 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ViewRay, Inc
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 12, 2019 to file lead plaintiff applications in a securities class action lawsuit against ViewRay, Inc. (NasdaqGS: VRAY), if they purchased the Company’s shares between March 15, 2019 and August 8, 2019. This action is pending in the United States District Court for the Northern District of Ohio.
Nov 08, 2019 04:21 pm ET
VRAY NOTICE: Zhang Investor Law Reminds Investors of November 12 Deadline in Securities Class Action Lawsuit Against ViewRay, Inc.- VRAY
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of ViewRay, Inc. (NASDAQ: VRAY) between March 15, 2019 and August 8, 2019 inclusive (the “Class Period”). If you wish to serve as lead...
Nov 08, 2019 03:00 pm ET
INVESTOR ALERT - ViewRay, Inc. (VRAY) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: November 12, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ViewRay, Inc.  (“ViewRay”  or “the Company”) (NASDAQ: VRAY) and certain of its officers, on behalf of shareholders who...
Nov 08, 2019 11:16 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GNLN, SNDL, VRAY and SDC
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 07, 2019 09:11 am ET
CLASS ACTION UPDATE for COF, SNDL, VRAY and CC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 06, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN)Class...
Nov 06, 2019 05:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against ViewRay, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of Ohio on behalf of all investors that purchased ViewRay, Inc. (NASDAQ: VRAY) securities between March 15, 2019 and August 8, 2019 ("the "Class Period").  Investors have until November 12, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Nov 05, 2019 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of FTCH, GNLN, OLLI and VRAY
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed are encouraged to contact us...
Nov 05, 2019 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ViewRay, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of ViewRay, Inc. (“ViewRay” or the “Company”) (NASDAQ: VRAY) investors who...
Nov 05, 2019 09:40 am ET
Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against ViewRay, Inc. (VRAY) and November 12 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against ViewRay, Inc. (“ViewRay” or the “Company”) (NASDAQ: VRAY), and certain other defendants, related to alleged violations of federal securities laws
Nov 04, 2019 11:00 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of VRAY and OLLI of Upcoming Deadlines
Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies: ViewRay, Inc. (NASDAQ GS: VRAY) Class Period: March 15, 2019 – August 8,...
Nov 04, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN) Class Period: shares issued either in or after the April 2019 initial...
Nov 04, 2019 08:15 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies ViewRay (VRAY) Investors of 8-Day Application Deadline, Encourages Investors Who Suffered Significant Losses to Contact Firm Now
Hagens Berman reminds investors in ViewRay, Inc. (NASDAQ: VRAY) of the November 12, 2019 lead plaintiff deadline in a securities fraud class action pending against the company and urges VRAY investors who have suffered losses in excess of $50,000...
Nov 04, 2019 09:20 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PUMP, MGNX, VRAY and DOMO
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 01, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN)Class Period:...
Nov 01, 2019 03:00 pm ET
Shareholder Alert - Greenlane Holdings, Inc. (GNLN), MacroGenics, Inc. (MGNX) & ViewRay, Inc. (VRAY)  - Bronstein, Gewirtz & Grossman, LLC Class Actions
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Nov 01, 2019 01:06 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in PUMP, VRAY, and MDP of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of PUMP, VRAY, and MDP. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Nov 01, 2019 11:00 am ET
DEADLINE ALERT for VRAY, CADE, OLLI, and WTRH: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 01, 2019 10:54 am ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against ViewRay, Inc.– VRAY
Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of ViewRay, Inc. (Nasdaq: VRAY) from March 15, 2019 through August 8, 2019 inclusive (the “Class Period”). The lawsuit seeks to recover damages for...
Oct 31, 2019 09:41 am ET
CLASS ACTION UPDATE for ADTN, MDP, MGNX and VRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 30, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN) Class Period: shares issued either in or after the April 2019 initial...
Oct 30, 2019 04:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics, ViewRay, Cadence Bancorp, and ProPetro and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of MacroGenics, Inc. (NASDAQ: MGNX), ViewRay, Inc. (NASDAQ: VRAY), Cadence Bancorp...
Oct 29, 2019 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of FTCH, GNLN, OLLI and VRAY
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed are encouraged to contact us...
Oct 29, 2019 08:06 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds ViewRay (VRAY) Investors of Lead Plaintiff Deadline: Investors Who Have Suffered Significant Losses Encouraged to Contact the Firm Now
Hagens Berman reminds investors in ViewRay, Inc. (NASDAQ: VRAY) of the pending securities fraud class action and urges VRAY investors who have suffered losses in excess of $50,000 to contact the firm. Class Period: Mar. 15, 2019 - Aug. 8, 2019...
Oct 28, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN)Class Period:...
Oct 28, 2019 08:15 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of VRAY and OLLI of Upcoming Deadlines
Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies: ViewRay, Inc. (NASDAQ GS: VRAY) Class Period: March 15, 2019 – August 8, 2019Lead Plaintiff...
Oct 28, 2019 05:45 pm ET
ROSEN, A HIGHLY RANKED LAW FIRM, Reminds ViewRay, Inc. Investors of Important Deadline in Securities Class Action – VRAY
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ViewRay, Inc. (NASDAQ: VRAY) from March 15, 2019 through August 8, 2019, inclusive (the “Class Period”) of the important November 12, 2019 lead plaintiff...
Oct 28, 2019 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ViewRay, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of ViewRay, Inc. (“ViewRay” or the “Company”) (NASDAQ: VRAY) investors who...
Oct 25, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN) Class Period: shares issued either in or after the April 2019 initial...
Oct 25, 2019 03:50 pm ET
Zhang Investor Law Reminds Investors of November 12 Deadline in Securities Class Action Lawsuit Against ViewRay, Inc.- VRAY
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of ViewRay, Inc. (NASDAQ: VRAY) between March 15, 2019 and August 8, 2019 inclusive (the “Class Period”). If you wish to serve as lead...
Oct 25, 2019 03:00 pm ET
Class Action - MacroGenics, Inc. (MGNX), ViewRay, Inc. (VRAY) & Cadence Bancorporation (CADE) - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 25, 2019 09:41 am ET
SHAREHOLDER ALERT: MDP VRAY CVET RUHN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 24, 2019 11:00 am ET
DEADLINE ALERT for MDP, VRAY, CADE, and OLLI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 24, 2019 10:06 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRPT, VRAY, MTCH and TME
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 24, 2019 03:00 am ET
European Symposium to Advance Adoption of MRI-Guided Radiation Therapy
CLEVELAND, Oct. 24, 2019 /PRNewswire/ -- Clinicians interested in learning more about MRI-guided radiation therapy can attend a day-long symposium on Friday, November 14, 2019 in Rome to understand the strategic, economic, clinical and technical aspects of starting an MR-image guided radiation therapy program. The Symposium will feature presentations from various experts in MRI-guided radiation therapy and an update on the Health Economics in Radiation Oncology Project (HERO), titled "Access to Innovative Radiotherapy: How to Make it Happen from an Economic Perspective," given by co-chair an
Oct 23, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN)Class Period:...
Oct 23, 2019 07:09 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Canada Goose, Meredith Corporation, MacroGenics, and ViewRay and Encourages Investors to Contact the Fi
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Goose Holdings, Inc. (NYSE: GOOS), Meredith Corporation (NYSE: MDP),...
Oct 23, 2019 03:16 pm ET
VIEWRAY, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP announces that a  securities  class  action  lawsuit  has  been  filed  in  the  United States District Court for the Norther
Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of Ohio on behalf of investors that acquired ViewRay, Inc....
Oct 23, 2019 09:22 am ET
CLASS ACTION UPDATE for MGNX, VRAY, MTCH and CVET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 22, 2019 08:35 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, REMIND VIEWRAY (VRAY) INVESTORS OF SECURITIES CLASS ACTION: Firm Encourages Investors Who Have Suffered Losses to Contact the Firm Now
Hagens Berman reminds investors in ViewRay, Inc. (NASDAQ: VRAY) of the pending securities fraud class action and urges VRAY investors who have suffered losses in excess of $50,000 to contact the firm. Class Period: Mar. 15, 2019 – Aug. 8, 2019...
Oct 22, 2019 06:44 pm ET
VIEWRAY SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In ViewRay, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 22, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ViewRay, Inc. (NASDAQ: VRAY) ("ViewRay" or the "Company")  of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 22, 2019 02:31 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in PUMP, VRAY, and MDP of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of PUMP, VRAY, and MDP. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Oct 21, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN) Class Period: shares issued either in or after the April 2019 initial...
Oct 21, 2019 08:07 pm ET
VIEWRAY DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In ViewRay, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 21, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ViewRay, Inc. (NASDAQ: VRAY) ("ViewRay" or the "Company") of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 20, 2019 11:00 am ET
ROSEN, A LEADING LAW FIRM, Reminds ViewRay, Inc. Investors of Important November 12th Deadline in Securities Class Action – VRAY
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ViewRay, Inc. (NASDAQ: VRAY) from March 15, 2019 through August 8, 2019, inclusive (the “Class Period”) of the important November 12, 2019 lead plaintiff...
Oct 18, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN) Class Period:...
Oct 18, 2019 07:04 pm ET
VIEWRAY SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In ViewRay, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 18, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ViewRay, Inc. (NASDAQ: VRAY) ("ViewRay" or the "Company") of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 18, 2019 03:00 pm ET
Class Action - MacroGenics, Inc. (MGNX), ViewRay, Inc. (VRAY) & Cadence Bancorporation (CADE) - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 18, 2019 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ViewRay, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of ViewRay, Inc. (“ViewRay” or the “Company”) (NASDAQ: VRAY) investors who...
Oct 18, 2019 09:13 am ET
SHAREHOLDER ALERT: COF VAL VRAY CC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 17, 2019 12:39 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of VRAY and OLLI of Upcoming Deadlines
Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies: ViewRay, Inc. (NASDAQ GS: VRAY) Class Period: March 15, 2019 – August 8, 2019Lead Plaintiff...
Oct 17, 2019 09:03 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FTCH, VRAY, CC and RUHN
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 16, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN) Class Period: shares issued either in or after the April 2019 initial...
Oct 16, 2019 03:07 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in PUMP, VRAY, and MDP of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of PUMP, VRAY, and MDP. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Oct 15, 2019 08:54 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Macrogenics, ViewRay, Cadence Bancorp, and ProPetro and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Macrogenics, Inc. (NASDAQ: MGNX), ViewRay, Inc. (NASDAQ: VRAY), Cadence Bancorp (NYSE: CADE), and ProPetro Holding Corp....
Oct 15, 2019 08:06 pm ET
VRAY INVESTOR REMINDER: Hagens Berman Reminds ViewRay, Inc. (VRAY) Investors of Securities Class Action, Encourages Investors to Contact the Firm
Hagens Berman reminds investors in ViewRay, Inc. (NASDAQ: VRAY) of the pending securities fraud class action and urges VRAY investors who have suffered losses in excess of $50,000 to contact the firm. Class Period: Mar. 15, 2019 – Aug. 8, 2019...
Oct 15, 2019 08:01 pm ET
VIEWRAY DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In ViewRay, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 15, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ViewRay, Inc. (NASDAQ: VRAY) ("ViewRay" or the "Company")  of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 15, 2019 11:00 am ET
DEADLINE ALERT for VAL, MDP, VRAY, and CADE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 15, 2019 10:00 am ET
Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against ViewRay, Inc. (VRAY) and November 12 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against ViewRay, Inc. (“ViewRay” or the “Company”) (NASDAQ: VRAY), and certain other defendants, related to alleged violations of federal securities laws
Oct 15, 2019 08:30 am ET
ViewRay Announces Preliminary Third Quarter 2019 Results and Details of Upcoming Conference Call
CLEVELAND, Oct. 15, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019. The preliminary results have not been audited and are subject to change.
Oct 14, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN)Class Period:...
Oct 11, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS FTCH, GNLN, OLLI, VRAY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Greenlane Holdings, Inc. (GNLN)Class Period: shares issued either in or after the April 2019 initial...
Oct 11, 2019 03:00 pm ET
Class Action - MacroGenics, Inc. (MGNX), ViewRay, Inc. (VRAY) & Cadence Bancorporation (CADE) - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 11, 2019 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ViewRay, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of ViewRay, Inc. (“ViewRay” or the “Company”) (NASDAQ: VRAY) investors who...
Oct 11, 2019 09:24 am ET
SHAREHOLDER ALERT: PS NTAP VRAY CADE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 10, 2019 02:47 pm ET
CLASS ACTION UPDATE for VRAY, CADE, OSTK and CC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 10, 2019 11:38 am ET
VIEWRAY DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In ViewRay, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 10, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ViewRay, Inc. (NASDAQ: VRAY) ("ViewRay" or the "Company") of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 10, 2019 09:13 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NTAP, VAL, SNDL and VRAY
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.